Quantum-Si (QSI) to Release Earnings on Thursday

Quantum-Si (NASDAQ:QSI) is anticipated to post its quarterly earnings results after the market closes on Thursday, March 6th. Analysts expect Quantum-Si to post earnings of ($0.18) per share and revenue of $1.23 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Quantum-Si Trading Down 5.8 %

Shares of QSI stock opened at $1.30 on Tuesday. The stock has a market cap of $185.53 million, a P/E ratio of -2.03 and a beta of 2.69. The stock has a 50 day simple moving average of $2.23 and a 200 day simple moving average of $1.44. Quantum-Si has a 1 year low of $0.61 and a 1 year high of $5.77.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $5.50 price target on shares of Quantum-Si in a research note on Tuesday, January 14th. Canaccord Genuity Group lowered their price objective on shares of Quantum-Si from $1.50 to $1.00 and set a “hold” rating for the company in a research report on Wednesday, November 13th. Finally, Alliance Global Partners initiated coverage on shares of Quantum-Si in a research report on Friday, February 7th. They set a “buy” rating and a $3.75 price objective for the company.

Insider Buying and Selling at Quantum-Si

In other news, Director Jonathan M. Rothberg sold 3,506,267 shares of the company’s stock in a transaction on Friday, December 27th. The shares were sold at an average price of $3.34, for a total transaction of $11,710,931.78. Following the completion of the transaction, the director now directly owns 1,250,000 shares in the company, valued at approximately $4,175,000. This represents a 73.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 30.04% of the company’s stock.

About Quantum-Si

Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments.